MyFinsight
Home
Blog
About
Contact
Back
Cash Flow
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)
source: myfinsight.com
Download
Download image
Proceeds from issuance of
common shares
$7K
Net cash provided by
financing activities
$7K
(decrease)/increase in cash and cash
equivalents
-$6,504K
Canceled cashflow
$7K
Cost of share-based
payments
$1,850K
Net cash used in
operating activities
-$6,511K
Canceled cashflow
$1,850K
Net loss
-$6,050K
(decrease)/increase in accounts
payable
-$1,579K
Increase in employee
compensation and benefits
-$460K
Increase in other current
assets
$193K
(decrease)/increase in accrued
liabilities
-$79K
Back